DCTH

Business Context and Reporting Period

Company: Delcath Systems, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: Delcath is a development-stage company focused on the Delcath System, a medical device designed to isolate the liver from the general circulatory system to administer high-dose chemotherapy directly to liver tumors. The system is currently in Phase III clinical trials for the treatment of malignant melanoma metastatic to the liver using the drug melphalan. The company has no commercial revenue and relies on equity financing to fund operations.

Key Financial Metrics

Note: The 2007 Net Loss was significantly reduced by $2.7 million in non-cash derivative instrument income related to warrants issued in a September 2007 financing.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately 66.6% from $10.95 million in 2006 to $3.66 million in 2007. This improvement was primarily driven by the resolution of legal matters that incurred extraordinary costs in 2006 and the recognition of $2.7 million in derivative income.
• Expense Fluctuations: General and Administrative expenses dropped 70.3% year-over-year due to the absence of the 2006 legal costs. Conversely, Research and Development expenses increased 56.1% to $4.24 million, reflecting increased costs associated with the National Cancer Institute (NCI) Cooperative Research and Development Agreement (CRADA) and accelerated clinical development.
• Liquidity Increase: Cash and cash equivalents increased by approximately $1.6 million, bolstered by a registered direct offering in September 2007 that raised approximately $13.3 million in net proceeds.
• Derivative Liability: A new liability of $1.55 million was recorded in 2007 for warrants issued in the September financing, which are subject to mark-to-market adjustments.

Guidance, Outlook, Risks, and Unusual Items

• Clinical Trial Status: The company is conducting a pivotal Phase III trial for melanoma metastatic to the liver. In October 2007, the FDA recommended a temporary suspension of enrollment due to four serious gastrointestinal adverse events. Following a review and protocol amendments, the FDA authorized the resumption of trials in November 2007.
• Capital Requirements: Management believes current capital resources are sufficient to fund operations through 2008, provided no new studies outside the NCI CRADA are initiated. However, the company anticipates needing additional working capital after fiscal 2008 to commercialize the product.
• Legal Contingency: A libel lawsuit filed by the company against a former director was dismissed in April 2007. In March 2008, the Court of Appeals reversed the district court's denial of sanctions against the company, remanding the case to determine the appropriate amount. The defendant has claimed costs of $450,000, which the company disputes.
• Regulatory Risk: The company has no revenue and cannot market its product without FDA pre-market approval. Failure to obtain approval or secure additional funding would materially limit the company's ability to generate revenue.

Investor Verification Checklist

• Capital Runway: Verify if the company has secured additional funding beyond the $17.8 million cash on hand to cover commercialization costs post-2008.
• Clinical Trial Safety: Monitor the status of the Phase III trial and any further FDA communications regarding the gastrointestinal adverse events that caused the October 2007 suspension.
• Legal Sanctions: Track the outcome of the remanded sanctions proceeding regarding the dismissed libel lawsuit to assess potential liability exposure.
• Derivative Liability: Review future quarterly reports for mark-to-market adjustments on the warrant liability, which can significantly impact reported net income/loss.
• Supplier Dependency: Confirm the stability of sole-source suppliers for critical device components (B. Braun, Medtronic, and filter manufacturers) as the company scales toward commercialization.